Screener
IBB vs IDNA
iShares Biotechnology ETF vs iShares Genomics Immunology and Healthcare ETF
Key differences
- IBB is significantly larger than IDNA — larger funds tend to be more liquid and less likely to close.
- Over the last 3 years, IBB has delivered higher annualized returns.
- IBB has a longer track record, which may reduce uncertainty around long-term behavior.
Side-by-side comparison
| IBB | IDNA | |
|---|---|---|
| Annual cost (TER) | 0.44% | 0.47% |
| Fund size (AUM) | $7.9B | $160M |
| Since | 2001 | 2019 |
| Dividend yield | 0.23% | 1.05% |
| Asset class | equity | equity |
| Region | north america | — |
| Strategy | index tracking | index tracking |
| CAGR 1Y | +39.0% | +49.2% |
| CAGR 3Y | +9.6% | +8.0% |
| CAGR 5Y | +2.7% | -7.5% |
| Sharpe 3Y | 0.38 | 0.29 |
| Volatility 1Y | 19.75% | 24.43% |
| Max drawdown | -39.82% | -68.26% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to IBB and IDNA
Explore further